Abstract
Voriconazole is an antifungal agent that is commonly used in immunocompromised patients who develop fungal infections. We report a case of severe recurrent hyperkalemia that developed after starting voriconazole for the treatment of histoplasmosis in a kidney transplant patient who was maintained on tacrolimus-based immunosuppression. Hyperkalemia developed despite reducing the tacrolimus dose to maintain levels in a low therapeutic range. Although interactions between azoles and calcineurin inhibitors are widely recognized, this is the 1st report describing new-onset hyperkalemia following initiation of voriconazole in a kidney transplant patient receiving tacrolimus.
Cite
CITATION STYLE
Nazmul, M. N., Miles, C. D., & Westphal, S. G. (2017). Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report. Transplantation Proceedings, 49(10), 2372–2373. https://doi.org/10.1016/j.transproceed.2017.09.007
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.